Using PLK1 inhibitors to treat small cell lung cancer
Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer
This study is looking at new treatments for small cell lung cancer by testing drugs that target a specific enzyme, hoping to find better options for patients with this tough-to-treat cancer, especially those with certain genetic changes in their tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10888314 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for small cell lung cancer (SCLC), a type of lung cancer with a very low survival rate. The team is investigating the effectiveness of specific drugs that inhibit the polo-like kinase 1 (PLK1) enzyme, which has shown promise in preclinical tests. By analyzing various SCLC cell lines, they found that tumors with certain genetic mutations respond better to these inhibitors. The goal is to translate these findings into effective therapies for patients suffering from this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer, particularly those with mutations in the TP53 gene.
Not a fit: Patients with non-small cell lung cancer or those without the specific genetic mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with small cell lung cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown that targeting PLK1 can be effective in other cancer types, suggesting a promising avenue for SCLC treatment.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Owonikoko, Taofeek K — University of Maryland Baltimore
- Study coordinator: Owonikoko, Taofeek K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.